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Abstract
Background: Urinary tract infection (UTI) is a common infection that poses a substantial healthcare burden, yet its definitive
diagnosis can be challenging. There is a need for a rapid, sensitive and reliable analytical method that could allow early
detection of UTI and reduce unnecessary antibiotics. Pathogen identification along with quantitative detection of
lactoferrin, a measure of pyuria, may provide useful information towards the overall diagnosis of UTI. Here, we report an
integrated biosensor platform capable of simultaneous pathogen identification and detection of urinary biomarker that
could aid the effectiveness of the treatment and clinical management.
Methodology/Principal Findings: The integrated pathogen 16S rRNA and host lactoferrin detection using the biosensor
array was performed on 113 clinical urine samples collected from patients at risk for complicated UTI. For pathogen
detection, the biosensor used sandwich hybridization of capture and detector oligonucleotides to the target analyte,
bacterial 16S rRNA. For detection of the protein biomarker, the biosensor used an analogous electrochemical sandwich
assay based on capture and detector antibodies. For this assay, a set of oligonucleotide probes optimized for hybridization
at 37uC to facilitate integration with the immunoassay was developed. This probe set targeted common uropathogens
including E. coli, P. mirabilis, P. aeruginosa and Enterococcus spp. as well as less common uropathogens including Serratia,
Providencia, Morganella and Staphylococcus spp. The biosensor assay for pathogen detection had a specificity of 97% and a
sensitivity of 89%. A significant correlation was found between LTF concentration measured by the biosensor and WBC and
leukocyte esterase (p,0.001 for both).
Conclusion/Significance: We successfully demonstrate simultaneous detection of nucleic acid and host immune marker on
a single biosensor array in clinical samples. This platform can be used for multiplexed detection of nucleic acid and protein
as the next generation of urinary tract infection diagnostics.
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Introduction
Urinary tract infection (UTI) is a common bacterial infection
that affects all patient demographics. Diagnostic criteria include
presence of urinary symptoms (e.g. frequency, urgency, dysuria),
urinalysis showing pyuria, and urine culture showing $10
5 cfu/ml
uropathogen. For culture and the associated antimicrobial
susceptibility testing (AST), urine samples are sent to a clinical
microbiological laboratory, which has a typical delay of 2–3 days.
Due to this delay, physicians often prescribe antibiotics empirically
based on symptoms and historic antimicrobial susceptibility data.
While empiric treatment is sufficient in many patients, a more
complete diagnosis is beneficial for patients with recurrent,
complicated UTI such as those dependent on urinary catheters
for bladder emptying. Catheterized patients are prone to bacterial
colonization in the bladder that may not necessitate treatment (i.e.
asymptomatic bacteriuria) but are also at a greater risk of infection
with resistant pathogens due to frequent exposure to antibiotics
[1].
As a part of the host innate immune response, white blood cells
(WBCs) are recruited to the urinary tract in response to the
presence of bacterial pathogens. Typically, urinary WBC counts
are determined by urinalysis in a centralized laboratory or
approximated by a dipstick test at the point of care. Although
identification of pathogens gives useful information for diagnosis of
UTI, it does not distinguish colonization from infection, determine
severity of infection, or the degree of host response. Quantitative
detection of urinary proteins indicative of host immune response,
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hensive diagnosis of UTI and a significant advancement towards a
personalized medicine for UTI treatment [2].
There is significant interest to develop biosensor technology for
applications in healthcare, environmental, and food safety
monitoring [3,4]. Previously, we developed an electrochemical
biosensor for UTI diagnostics. This biosensor array consists of 16
individually addressable sensors that can be functionalized with
oligonucleotide probes or antibodies for detection of urinary
nucleic acids or proteins, respectively [5,6]. The detection strategy
is based on a sandwich assay, coupled to an HRP based redox
reaction, giving rise to quantifiable electrical signal.
Using the electrochemical biosensor, we demonstrated a 1-hour
biosensor assay for detection of pathogen 16S rRNA from patient
urine samples using the biosensor [7]. An advantage of this
electrochemical sensor platform is that it can be adopted for both
nucleic acids and protein detection. We have also developed an
immunoassay using the biosensor to detect lactoferrin (LTF), an
iron binding protein secreted by WBCs as part of innate immune
response [8]. Here we report an integrated biosensor assay for
simultaneous detection of nucleic acid and protein targets for UTI
diagnosis (Figure 1). We modified and expanded the panel of
oligonucleotide probes to target additional uropathogens and
optimized binding parameters for simultaneous pathogen and
protein detection. The integrated pathogen 16S rRNA and host
LTF assay was performed in 113 clinical urine samples collected
from patients at risk for complicated UTI. Data from the
integrated biosensor assay was compared with clinical laboratory
results and correlated with patient demographics.
Results
Development of oligonucleotide probe pairs optimized
for hybridization at 37uC
In our previous work, the biosensor assays for nucleic acids and
protein detection were based on target binding of nucleic acids at
65uC [5,6,7] and protein biomarkers at 37uC [8]. In an effort to
integrate the two assays on a single sensor array under uniform
target binding conditions (i.e. 37uC), we examined whether the
oligonucleotide probe pairs previously developed for hybridization
at 65uC can provide adequate signal strength and specificity at
37uC. Figure 2 shows representative experiments comparing the
specificity of the our previously reported probe pairs targeting E.
coli (EC449C-408D) and Enterococcus spp. (EF207C-171D) at 37uC
and 65uC hybridization. Overall, decreased signals and higher
cross-reactivity with other non-specific pathogens were observed at
37uC. Similar decrease in performance was observed with the 5
other probe pairs at 37uC (data not shown). Based on these
findings, we set out to develop a new set of probes optimized for
hybridization at 37uC to facilitate integration with the immuno-
assays.
A systematic approach of combining in silico predictions and
biosensor experiments was used to design and validate a panel of
new capture and detector probe pairs against bacterial 16S rRNA.
We selected 20–24 bp as the probe length for hybridization at
37uC, which is shorter than our previous probe pairs designed for
hybridization at 65uC [5,7], and longer than probes reported by
others for hybridization at room temperature [9]. Primrose [10]
software, in conjunction with the probe match function of
Ribosomal Database Project (RDP) [11], was used to identify
candidate capture probe sequences. For E. coli, 34 candidate probe
sequences were identified. To further narrow the selection,
Geneious sequence alignment software (Biomatters Inc, New
Zealand) [12] was used to match the candidate probes with a
database of 16S rRNA gene sequences from 133 uropathogenic
bacteria (three or more sequences of each common uropathogen).
For probes designed to target E. coli, this reduced the candidate
probe pairs from 34 to 5. Detector probes consisting of the
flanking sequence immediately upstream to the capture were
designed as previous work demonstrated that contiguous capture
and detector probes provide the best signal to noise ratio (SNR)
[6].
After the in silico selection process, 2–5 of the most promising
probe pairs for each pathogen were tested using the electrochem-
ical biosensor assay to determine their detection specificity and
sensitivity. Each of the probe pairs was tested against 15 different
uropathogens to determine their specificity. For example, 2 pairs
of E. coli probes were tested using the biosensor assay and the
probe pair EC471C-447D was selected for the clinical study since
it gave the best specificity and SNR. The probe pairs that gave the
optimal specificity and the best SNR are shown in Figure 3.
Table 1 shows the sequences of the capture and detector probe
pairs and their target pathogen(s). The threshold for positive
detection was defined as 3 standard deviations above the negative
Figure 1. Schematics of urine-based diagnostics for electrochemical biosensor detection of nucleic acids and proteins. (A) Schematic
of pathogen identification based on sandwich hybridization of bacterial 16S rRNA with capture and detector oligonucleotide probes; (B) Schematic of
immunoassay based on sandwich detection host urinary protein with capture and detector antibodies. The two assays share similar assay parameters,
including surface functionalization with biotinylated capture probes/antibodies, probe-target binding at 37uC, and amperometric detection using
horseradish peroxidase (HRP) as the signaling enzyme [7,8].
doi:10.1371/journal.pone.0026846.g001
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pairs. The universal (UNI) probe pair, which targets a highly
conserved region of 16S bacterial rRNA, detected all pathogens
tested. The EB probe pair targets the Enterobacteriaceae family,
which are gram-negative enteric bacteria that constitute majority
of the gram-negative uropathogens. Probe pairs targeting Proteus
mirabilis (PM), E. coli (EC), Pseudomonas aeruginosa (PA), Enterococcus
spp. (EF), Serratia marcescens (SM), Providencia (PS) and Staphylococcus
spp. (SA) showed specific detection of the respective species. For
the MM and KE probe pairs, the threshold for positive detection
was defined as 5 standard deviations above negative control in
order to maintain specificity, with minor compromise of
sensitivity. Using this threshold, the MM probe provides specific
detection of Morganella morganii. Given the similarity in the 16S
rRNA sequences for the Klebsiella, Enterobacter,a n dCitrobacter spp.,
KE probe pair has specificity for Klebsiella pneumoniae, Klebsiella
oxytoca, Enterobacter cloacae, Enterobacter aerogenes and Citrobacter
freundii.
The limit of detection (LOD) of the biosensor assay was
10
4 cfu/ml from bacterial culture and clinical urine samples.
Similar to our previous results [5,6,7] urine samples have the
similar LOD as bacterial culture. The molar sensitivity of the assay
can be estimated through the number of 16S rRNA copies per
bacterial cell. This concentration reportedly varies between 7,000
and 70,000 ribosomes/cell [13,14] depending on the bacterial
species and its growth stage at the time of lysis. We thus estimate
the limit of detection of the sensor between 2–20 pM.
Patient and sample characteristics
In order to validate the new probe pairs in an integrated
biosensor assay combining pathogenic nucleic acids and host
protein biomarker detection, we used clinical urine samples
collected from spinal cord injury (SCI) patients, who are at
significant risks of developing complicated, polymicrobial urinary
tract infections due to neurogenic bladder and frequent use of
catheters. From 111 patients recruited (109 male, mean age
59613), 113 samples were analyzed, 85 from outpatients and 28
from inpatients. In our study population, 27 samples were
collected through spontaneous voiding, 85 samples from catheters,
and 1 sample from a patient with ileovesicostomy. Of the 85
catheterized samples, 21 were from standard indwelling Foley
catheter, 21 from clean intermittent catheterization, 11 from
suprapubic (SP) catheter, and 32 from condom (C) catheter.
Table 2 shows the characteristics of the urine samples as
reported by the clinical microbiology laboratory. Positive urine
culture was found in 79 samples, out of which 22 contained a
single species, 13 had two or three bacterial species and 44 samples
were reported as mixed urogenital flora. Similar to our prior
observations [7], E. coli was the most common pathogen followed
by K. pneumoniae. P. aeruginosa was the most common pathogen
found in samples containing two species.
Clinical validation using the integrated biosensor array
The collected urine samples were tested using the integrated
biosensor array for quantitative detection of pathogen(s) and LTF.
Each urine sample was tested with a single 16-sensor array. The
sensors were functionalized with the new panel of the capture
probes against 16S rRNA and the capture antibody against LTF.
Both hybridization and the antibody-antigen binding steps were
performed at 37uC. Figure 4 shows the output from the integrated
biosensor assay for analysis of a patient urine sample. The
biosensor results were compared with clinical microbiology
laboratory results for culture and urinalysis. Consistent with the
clinical microbiology report, the biosensor assay identified the
presence of E. coli and significant pyuria.
Of the 34 samples that were culture negative, biosensor results
agreed with clinical microbiology in all but one sample, yielding a
specificity of 97%. In this particular sample, the clinical
microbiology laboratory reported it to be culture negative, while
independent culturing in our laboratory indicated 4610
7 cfu/ml
bacteria. The clinical microbiology laboratory reported 79 samples
as culture positive, out of which biosensor detected 70 as positive,
yielding a sensitivity of 89%. The samples that were not detected
by the biosensor had bacterial concentrations ranging from 10
3 to
10
4 cfu/ml, which was at or below the LOD of the biosensor
assay.
The biosensor assay detected bacteria in all 22 urine samples
containing a single uropathogen and further identified the
bacterial species in 16 of these samples and the family (e.g.
Enterobacteriaceae) in 6 samples, with results in agreement with the
clinical microbiology results. Samples that were identified to the
family level included the samples containing K. pneumoniae and E.
aerogenes, which were targeted by the KE, EB, and UNI probes on
the biosensor.
The majority of the samples with polymicrobial infection were
reported as ‘mixed flora’ and not speciated by the clinical
Figure 2. Comparison of biosensor pathogen detection using 35-bp probes at 65 and 376C. Probe selectivity and sensitivity was tested
against different uropathogens. A. The biosensor signal for detection of E. coli with EC449C-EC08D was 1996 nA at 65uC compared to 1270 nA at
37uC and this probe set showed non-specific binding with K. oxytoca at both temperatures. B. The biosensor signal for detection of E. faecalis with
EF207C-EF171D was 1107 nA at 65uC and 549 nA at 37uC and this probe set showed non-specific binding with K. pneunomiae, E. cloacae, S. aureus, S.
epidermidis. The bacterial species are abbreviated on the X-axis with capital letter for genus and small letter for species.
doi:10.1371/journal.pone.0026846.g002
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the biosensor results at the species level. Out of the 44 ‘mixed’
samples identified by the clinical microbiology laboratory, the
biosensor detected 37 of these samples as positive by the UNI
probe. The bacterial concentration in four of the missed samples
was below the biosensor’s limit of detection.
Of the 13 polymicrobial samples that were speciated, the
biosensor accurately identified all species in four of these samples
and at least one of the species in six samples. The samples missed
by the biosensor either had pathogens below the limit of the
detection of the biosensor or specific probes for the pathogens
were not available.
LTF concentration was determined in each urine sample along
with the detection of pathogens by 16S rRNA in the integrated
biosensor assay. Data from the integrated biosensor assay was
correlated with results obtained from urinalysis. Spearman’s
Figure 3. Specificity of biosensor pathogen detection with 20–24 bp oligonucleotide probes designed for hybridization at 376C.
Log signal intensities of current (nA) are plotted on the Y-axis. Common uropathogens tested are indicated on the X-axis. The line over the bars
indicates the threshold for positive biosensor signal 3SD (log10 unit) over the negative control for UNI, EB, PM, EC, PA, EF, SM, PS, SA and 5SD (log10
unit) over negative control for MM and KE probes. Consistent with their in silico design, UNI probe pair detected all bacterial species and EB probe
pair detected members of Enterobacteriaceae. PM, EC, PA, EF, SM, PS, SA and MM probe pairs specifically detected Proteus mirabilis, E. coli,
Pseudomonas aeruginosa, Enterococcus spp., Serratia marcescens, Providencia spp., Staphylococcus spp, and Morganella morganii, respectively. The KE
probe pair detected Klebsiella pneumoniae, Klebsiella oxytoca, Citrobacter freundii, Enterobacter aerogenes and Enterobacter cloacae. Probe sequences
are provided in Table 1.
doi:10.1371/journal.pone.0026846.g003
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different clinical parameters, bacterial and LTF concentration.
Consistent with our previous report [8], we found a significant
correlation between LTF concentration measured by the biosensor
and WBC (r=0.56, p,0.001) and leukocyte esterase (r=0.76,
p,0.001) reported by urinalysis. A significant correlation was also
found between bacterial concentration and LTF concentration
(r=0.61,p,0.001), WBC (r=0.53,p,0.001) and leukocyte esterase
(r=0.67, p,0.001 for each). Similar correlations between bacterial
concentrations and WBC have been reported previously [15,16,17].
Discussion
System integration is one of the most challenging aspects of
developing point-of-care diagnostics [18,19]. One of the goals of
the current study is integrated detection of two different targets,
bacterial nucleic acids (i.e. 16S rRNA) and host protein (i.e. LTF)
onto a single biosensor platform. We present clinical validation of
an electrochemical biosensor array for UTI diagnosis capable of
pathogen identification by detection of bacterial 16S rRNA and
assessment of pyuria by detection of LTF. While our previous
work demonstrated independent biosensor assays for pathogen
identification and LTF [5,7,8], here we have modified the assay to
allow integration of the assays on a single biosensor array at 37uC
without loss of sensitivity or specificity.
For this study, we developed new panel of oligonucleotide
probes for pathogen identification that facilitate integration with
synchronous protein detection under common assay conditions.
While nucleic acid detection works well at higher temperature
[5,7], protein detection may be compromised at high temperatures
due to decreased stability or aggregation of proteins [20]. In our
earlier studies, oligonucleotide probes designed for hybridization
at 65uC were used for detection of bacterial 16S rRNA. These
probes showed reduced sensitivity and specificity at 37uC.
We have expanded our probe panels to target additional
uropathogens including Serratia, Providencia, Morganella and Staphy-
lococcus, which represents significant progress towards development
of a comprehensive panel for detection of clinically significant
uropathogens. The shorter probe length of 20–24 bp allowed
targeting a greater number of regions of sequence diversity within
16S rRNA. The lower hybridization temperature not only
facilitates integration of the nucleic acid assays and immunoassays,
but will also be useful for further integration with a biosensor-
based antimicrobial susceptibility test, which is also done at 37uC
[21].
We successfully demonstrated simultaneous detection of nucleic
acid and host immune marker on a single biosensor array in
clinical samples. The two electrochemical assays share similar
protocol parameters, including surface functionalization with
biotinylated capture probes/antibodies, probe-target binding at
37uC, and amperometric detection using horseradish peroxidase
(HRP) as the signaling enzyme. Furthermore, integration improves
the efficiency and reduces the potential human errors associated
Table 1. Sequences of the oligonucleotide probes used in this study.
Probe pairs (Length in bp) Sequence (59-39) Species detected
UNI798C (22) TCGTTTACRGCGTGGACTACCA Ec, Mm, Kp, Pm, El, Ea, Cf, Cb, Ko, Ps, Sm, Sf, Pr
UNI776D (22) GGGTATCTAATCCTGTTTGCTC Pa, Ef, Ee Sa, Se, Ss, Pv, Kz, Xm, Dp, Ab, Af, Fi
EB1275C (23) ACTTTATGAGGTCCGCTTGCTCT Ec, Mm, Kp, Kz, Pm, El, Ea, Cf, Ko, Ps, Sm, Pr, Sf,
EB1252D (23) CGCGAGGTCGCCTTCCTTTGTAT Cb
PM1019C (22) AGCGTTCCCGAAGGCACTCCTC Pm, Pv
PM997D (22) TATCTCTAAAGGATTCGCTGGA
EC471C (24) CTGCGGGTAACGTCAATGAGCAAA Ec
EC447D (24) GGTATTAACTTTACTCCCTTCCTC
PA594C (23) CCCGGGGATTTCACATCCAACTT Pa
PA570D (23) GCTGAACCACCTACGCGCGCTTT
EF220C (20) ACCGCGGGTCCATCCATCAG Ef, Ee
EF200D (20) CGACACCCGAAAGCGCCTTT
SM472C (22) TGCGAGTAACGTCAATTGATGA Sm
SM450D (22) RCGTATTAAGYTCACCACCTTC
PS151C (24) CCGAAGGTCCCCTGCTTTGCTCCT Ps, Pr
PS127D (24) AAGAGATTATGCGGTATTAGCCAC
SA91C (22) CCCGTCCGCCGCTAACRTCAGA Sa, Se, Ss
SA69D (22) GRAGCAAGCTYCTCGTCYGTTC
MM181C (22) GGCGCGAGGCCCGGAGGTCCCC Mm
MM147D (22) CGCTTTGGTCCGAAGACATTAT
KE468C (22) AGTAACGTCAATCRCYAAGGTT Ea, El, Kp, Cf, Ko, Kz, Cb
KE446D (22) ATTAACCTTAACGCCTTCCTCC
The capture (denoted by ‘‘C’’) and detector (denoted by ‘‘D’’) probes were modified with 59 biotin and 39 fluorescein, respectively. The degenerate bases R represents
bases A or G and Y represents C or T. E. coli (Ec), M. morganii (Mm), K. pneumoniae (Kp), K. ozaenae (Kz), P. mirabilis (Pm), P.vulgaris (Pv), E. faecalis (Ef), E. faecium (Ee), E.
cloacae (El), E. aerogenes (Ea), C. freundii (Cf), C. braackii (Cb), P. aeruginosa (Pa), K. oxytoca (Ko), A. baumannii (Ab), P. stuartii (Ps), P. rettgeri (Pr), S. aureus (Sa), S.
marcescens (Sm), S. fonticola (Sf), S. epidermidis (Se), S. saprophyticus (Ss), X. maltophilia (Xm), Diphtheroids (Dp), A. baumannii (Ab), A. faecalis (Af), F. indolgenes (Fi) were
tested against above probe sets.
doi:10.1371/journal.pone.0026846.t001
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culture negative, was found to have significant pyuria (75–100
WBC/HPF) and bacteria by microscopy in separate clinical
laboratory urinalysis. In our integrated assay, we found this sample
to be biosensor positive for UNI, EB and KE probes and
contained 9950 ng/ml of LTF. Independent plating in our
laboratory further corroborated pathogen identification, indicating
the presence of 4610
7 cfu/ml bacteria.
LTF is a molecular marker of pyuria [8,22], and urinalysis
measurement of pyuria is routinely performed as part of UTI
diagnosis. Previous studies have suggested LTF as a promising
biomarker for UTI diagnosis [2,22]. Given the relative abundance
in urine, LTF also serves as a suitable target for new assay
development using the electrochemical biosensor. In this study we
examined the utility of measuring LTF in urine samples of spinal
cord injury (SCI) patients. These patients are at risk for
complicated UTI, due to structural and physiological impairment
of bladder emptying, vesicoureteral reflux, and need of indwelling
catheters [23]. In this study, the LTF concentration was highly
correlated with WBC concentration and leukocyte esterase. While
the analytical performance of the integrated assay was promising,
we found that LTF level was not predictive of the need for
treatment. This is likely due to the association of asymptomatic
pyuria associated with urinary catheters, which is common in SCI
patients [23,24]. Future directions include validation of the
integrated assay in non-catheterized patients and identification
of biomarkers specific to infection in catheterized patients. Our
platform will enable efficient integration of additional biomarkers
with pathogen identification.
Rapid molecular diagnosis of UTI represents a significant
advance in the management of UTI and potentially reduce the
practice of prescribing unnecessary antibiotics [25]. We have
developed a biosensor platform that enables multiplexed detection
of bacterial-specific nucleic acids and host immune response
protein, and demonstrated its validity in clinical samples. Efforts
are underway to improve the detection sensitivity of the assay by
incorporating electrokinetic manipulation on the biosensor
platform [26]. In the future, we intend to utilize this capability
and explore multiplexed detection of additional host immune
response biomarkers in order to better differentiate bacteriuria
from urinary tract infections.
Methods
Ethics statement
Patient urine samples were collected with approval from
Stanford University’s Institutional Review Board (IRB) and
Veterans Affairs Palo Alto Health Care System’s (VAPAHCS)
Research and Development committee. Oral informed consents
were obtained from all study subjects due to spinal cord related
physical impairment and low risk nature of the study. Oral consent
was approved by both Stanford IRB and VAPAHCS R&D
committee and was documented with a written record of
participants name, date of birth, medical record number and
date of sample collection, which served as both the record of oral
consent and enrollment record.
Design of oligonucleotide probes for pathogen detection
Oligonucleotide probes targeting the 16S rRNA of uropatho-
gens were designed using Primrose v2.17 and RDP Release 8. The
selectivity of the potential probes identified by Primrose was
assessed using the probe match function of RDP Release 10. Probe
selectivity was further verified by alignment against 16S rDNA
sequences from bacterial isolates from urine (at least 3 sequences
for each species) using Geneious. 16S rRNA gene sequences from
bacterial isolates were kindly provided by David Haake (unpub-
lished data).
Oligonucleotide probes are designated as capital letters to detect
all Eubacteria (UNI), P. mirabilis (PM), E. coli (EC), P. aeruginosa
(PA), Enterococcus spp. (EF), S. marcescens (SM), Providencia spp., (PS),
M. morganii (MM), Staphylococcus spp. (SA), K. pneumoniae, K. oxytoca,
E. cloacae, E. aerogenes, C. freundii (KE). UNI and EF probe pairs
were designed from the existing probe-pairs for hybridization at
65uC [5]. The probe pair targeting Enterobacteriaceae (EB) family
was previously described [9]. The oligonucleotide probe pairs (20–
24 bp) were synthesized by Integrated DNA Technologies Inc
(San Diego, CA).
Bacterial strains and cultivation
To validate their selectivity, oligonucleotide probes were tested
against uropathogen isolates from patient urine samples obtained
at VAPAHCS as well as strains obtained from American Type
Culture Collection (ATCC): C. freundii 8090, Enterococcus faecalis
49532, P. aeruginosa 10145, E. aerogenes 13048, E. cloacae 13047, K.
oxytoca 49131, and A. baumannii 19606. Uropathogen isolates from
patient samples were identified by clinical microbiology laboratory
analysis and confirmed by 16S rRNA gene sequencing (Sequetech,
USA) using the primers 8UA/907B and 774A/1485B [27].
Bacterial strains were grown in Luria Bertani broth to logarithmic
phase as measured by OD600. The bacterial concentration was
determined by serial dilution and plating. Bacterial cell pellets
containing 10
8 cfu were used for probe validation.
Table 2. Sample characteristics.
Number of samples
No growth 34
Single species 22
E. coli 9
K. pneumoniae 4
Enterococcus spp. 2
P. mirabilis 2
P. aeruginosa 2
M. morganii 1
C. koseri 1
E. aerogenes 1
2–3 species 13
E. coli, E. cloacae 1
E. coli, S. agalactiae 1
P. aeruginosa, Enterococcus spp. 2
P. aeruginosa, A. baumannii 1
P. aeruginosa, S. aureus 2
P. aeruginosa, K. pneumoniae 1
S. marcescens, S. agalactiae 1
Enterococcus spp., K. pneumoniae 1
K. pneumoniae, Lactose-Neg Gram-Neg Rod 1
P. aeruginosa, P. stuartii, S. aureus 1
P. mirabilis, Enterococcus spp. 1
Mixed urogenital flora 44
doi:10.1371/journal.pone.0026846.t002
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The electrochemical biosensor array (GeneFluidics, USA)
surface was functionalized as described previously [5,6], with the
following modifications: EZ-link Amine-PEG2-Biotin (Pierce,
Rockford, IL) concentration was 0.5 mg/ml in 0.1 M phosphate
buffer and the streptavidin (Sigma-Aldrich, St. Louis, MO)
concentration was 0.05 mg/ml in phosphate buffer containing
2.5% BSA. Six ml of the reagents and analytes were spotted on the
sensor. Sample preparation, sandwich hybridization of oligonu-
cleotide probes against bacterial 16S rRNA and amperometric
detection were performed as previously described [6], with the
exception that the hybridization steps were performed at 37uC.
Phosphate buffer (1 M, pH 7.2) containing 2.5% BSA with the
detector probe was used as a negative control.
Study participants and clinical samples
Urine samples were collected from the VAPAHCS spinal cord
injury unit between July 2009 and April 2010. The decision to
collect urine was based on clinical judgment of the treating
physician (patients suspected of a UTI or as part of their routine
care). Depending on the patient’s bladder emptying status, urine
samples were collected from an indwelling catheter, straight
catheterization, or voiding. For each sample, one aliquot was used
for the biosensor experiment and the second was sent to clinical
laboratory for urinalysis (white blood cells per high power field
(WBC/HPF), pH, specific gravity, leukocyte esterase, nitrite) and
culture and susceptibility. Qualitative and quantitative plating was
done in our laboratory on BBL CHROMagar
TM Orientation and
TSA with 5% sheep blood (BD Diagnostics, Sparks, MD) and LB
Figure 4. Example of integrated bacterial 16S rRNA and LTF biosensor assay from a urine specimen. Each array consisted of 16
electrochemical biosensors. In this study, eleven sensors were used for nucleic acid assay for pathogen identification and 5 sensors for immunoassay
for LTF detection. For measurement of LTF directly from urine, two urine dilutions were tested and the concentration of LTF was determined using
the standard curve generated from three known concentrations of LTF. For this urine sample, positive signals from the UNI, EB and EC probes
indicated this sample contained E. coli and the measured LTF concentration of 2106 ng/ml indicated significant pyuria. This interpretation was
confirmed by the clinical microbiology laboratory, which determined the sample contained .100,000 cfu/ml E. coli and .100 WBC/HPF. Inset shows
the standard curve for detection of LTF based on 123 measurements on different biosensors on different days. The results show good reproducibility
and could potentially be used for detecting the concentration of LTF from urine samples without the need of a standard curve on each biosensor.
doi:10.1371/journal.pone.0026846.g004
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1.5 ml of the sample was centrifuged and the pelleted fraction was
stored. Whole urine was stored for the LTF biosensor immuno-
assay. The samples were stored at 280uC until tested.
Integrated nucleic acid and protein biosensor assay
For the integrated assay, the surface of 11 of the 16 sensors on
the array was functionalized with the capture probes for pathogen
identification and 5 sensors were functionalized with capture
antibodies for LTF detection (rabbit biotinylated polyclonal anti-
LTF, ab25811, Abcam). The biosensor with the capture probes
and antibody was incubated at 37uC for 30 min. The urine pellet
was lysed as previously described [5] with the addition of
0.25 mg/ml of lysostaphin (Sigma, St Louis, MO) to the lysis
buffer. The lysate was neutralized with 50 ml of phosphate buffer
containing 2.5% BSA and divided to 11 aliquots of 6 ml each.
Different detector probes [1 ml of 0.5 mM in phosphate buffer
(pH 7.2) with 2.5% BSA] were added to each aliquot and
incubated at 37uC for 15 min for hybridization of the bacterial
16S rRNA to the detector probe. The detector probe-16S rRNA
complex was deposited on sensors containing the corresponding
capture probe. For LTF detection, LTF standards at 100, 25,
3.1 ng/ml and 1006 and 306 diluted urine samples were
deposited on electrodes with detector antibody-LTF complex.
Biosensor assay was completed as described previously [8].
Data analysis
Clinical microbiology results were used as the standard to
determine the diagnostic sensitivity and specificity of the biosensor
assay for pathogen identification. Per VAPAHCS clinical
microbiology laboratory protocol, samples containing bacterial
concentrations of 10,000 cfu/ml or less were not speciated. In
addition, polymicrobial samples containing 3 or more species were
typically not speciated and reported as mixed flora. Similar to our
previous report, signal from UNI probe was used to calculate the
diagnostic sensitivity of the biosensor [7]. Biosensor signals were
log10 transformed and positive signals were defined as greater than
3 SD (log10 units) over negative control for UNI, EB, PM, EC, PA,
EF, SM PS and SA probes and greater than 5 SD (log10 units) over
negative control for MM and KE probes. The lowest signal on the
biosensor assay was used as the negative control.
The urinary LTF concentrations were compared with results
obtained from urinalysis (WBC/HPF and leukocyte esterase) to
assess validity of the biosensor. To facilitate analysis, WBC/HPF
obtained from urinalysis were divided into four groups (0–2, 3–10,
11–50, .50). Samples containing ,2 WBC/HPF were considered
negative for pyuria. Descriptive analyses and ranked medians
among categorical groups were conducted using Kruskal-Wallis
test with GraphPad Prism version 5.0b. Spearman correlations
were performed using SAS version 9.1.3 to assess ranked
correlation between clinical and biological variables.
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